Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

Gilead Sciences (NASDAQ:GILD) is in focus after it set the timing for its next financial results update as biopharma earnings ...

In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous ...

In the latest close session, Gilead Sciences (GILD) was down 3.72% at $129.83. The stock's performance was behind the S&P 500's daily gain of 0.42%. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a ...

GILD recently won FDA approval for the label expansion of breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or ...

This morning a "Potential Dividend Run Alert" went out for Gilead Sciences Inc (NASD: GILD), at our DividendChannel.com Dividend Alerts service (a free email alerts feature). Let's look at the ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best ...

Gilead Sciences (GILD) shares snapped a six-session losing streak, closing 0.56% higher at $133.64 on Thursday. The biopharmaceutical company began its downward trend on April 15, and the stock lost ...

Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, after ...